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Abstract
Introduction. Every winter seasonal influenza and other viral respiratory infections increase pressure on the health services 
and are associated with nosocomial infection and morbidity.
Aim. To compare provision of point- of- care (POC) testing with laboratory- based testing for influenza and RSV detection on an 
adult respiratory assessment unit to assess the impact on isolation practices and length of stay (LOS).
Methodology. Prospective interrupted ‘on- off’ study in adults admitted to the respiratory unit between December 2018 and 
April 2019 with a suspected respiratory tract infection. Nasopharyngeal samples were tested using either the GeneXpert rapid 
POC test for influenza and RSV (on- period), or were sent to the laboratory for multiplex PCR testing against a panel of 12 res-
piratory viruses (off- period). Outcome measures were time to patient isolation for infection control, LOS and turnaround time 
from admission to test results.
Results. Of 1145 patients evaluated, 755 were tested with POC and 390 with laboratory multiplex; a respiratory virus was iden-
tified in 164 (21.7 %) and 138 (35.4 %) patients respectively. A positive POC test was associated with a shorter time to isolation 
(mean difference 16.9 h, P<0.001), shorter LOS (mean difference 15.5 h, P=0.05,) and shorter turnaround time (mean difference 
28.3 h, P<0.001), compared to laboratory testing.
Conclusion. Use of GeneXpert POC testing for Flu/RSV is associated with rapid reporting of results with significant improve-
ments in isolation practices and reductions in LOS.
InTRoduCTIon
Influenza and other viral respiratory infections are common 
and put considerable pressure on the health services each 
winter in the UK, as well as burdening patients, families and 
carers, and having a wider socio- economic impact [1]. Some 
patients will be hospitalised as a result of their infection and 
a small number will die from complications [2].
There is a growing body of evidence that rapid detection of 
viral respiratory infections through testing patients as soon as 
possible after they are admitted to hospital allows more timely 
and targeted management of illness [3]. For example, antiviral 
drugs may be started more quickly and appropriately and 
unnecessary antibiotics stopped earlier [4–8]. Additionally, 
rapid diagnosis may offer the potential to decrease transmis-
sion to other patients and staff by rapid instigation of relevant 
infection prevention and control precautions [7, 9, 10], and 
may assist clinicians to make decisions earlier regarding 
discharge of infected patients, potentially reducing their 
length of stay in hospital and easing pressure on hospital 
beds [11].
The symptoms and signs of influenza may overlap with those 
seen with other respiratory pathogens, making diagnosis 
based on clinical presentation alone challenging [12]. Diag-
nostic testing is therefore useful to guide appropriate clinical 
management, with the current gold- standard being detec-
tion of viral RNA by reverse transcriptase polymerase chain 
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reaction (RT- PCR), conducted in a specialised laboratory. 
However, although RT- PCR can produce a result within 4–8 h, 
transportation to the laboratory and batching of specimens 
the time to receipt of result may be considerable longer [13].
Point- of care (POC) tests are medical diagnostic tests 
performed by healthcare professionals on the ward who are 
trained in the use of the point- of- care analyser machines but 
are not laboratory staff. Results are available soon after testing. 
Second generation POC testing platforms using nucleic acid 
amplification technologies are now entering into clinical use 
and have been shown to have sensitivities and specificities of 
>90 % compared to first generation rapid influenza diagnostic 
tests [14].
One randomised controlled trial found an association with 
improved turnaround time, reduced length of stay and 
improved anti- viral use in the patient group which had point 
of care respiratory virus testing as opposed to standard lab 
testing [15]. Since then, in the UK, an increasing number of 
hospitals have started to introduce POC testing for respira-
tory viruses and some centres have reported their experiences 
[10, 16]. Most of these evaluations have been ‘before- after’ 
analyses focusing on length of stay, or hospital admission, as 
the primary outcome.
One of the expected benefits of POC testing is the more rapid 
availability of microbiological information to guide infection 
control decision- making and hence improve patient flow 
through hospital systems. Such benefits apply to both patients 
testing positive and those testing negative for respiratory 
viral infections. However, there are few published data on 
the magnitude of this benefit. We sought to determine the 
impact a PCR- based POC strategy for detecting respiratory 
viral infections on the institution of appropriate infection 
control measures and length of hospital stay, using an inter-
rupted ‘on- off ’ study design.
METHodS
We conducted a prospective interrupted ‘on- off ’ study as part 
of a clinical evaluation programme comparing two strategies 
for detecting respiratory virus infections in adults presenting 
to hospital with symptoms of an acute respiratory tract infec-
tion (ARTI).
Adults (aged >16 years) admitted to the Respiratory Assess-
ment Unit (RAU) at a large teaching hospital between 3 
December 2018 and 5 April 2019 with a clinically suspected 
ARTI had pharyngeal swabs taken as soon as possible after 
admission. The study period was divided into pre- specified 
control and intervention periods (7 and 11 weeks in total 
respectively)(Fig. 1). During the control period (weeks 1 to 5 
(3 December 2018 to 6 Jan 2019), week 10 (4–10 February) 
and week 14 (4 to 10 March)), samples were sent to the 
microbiology laboratory for testing against a panel of 12 
respiratory viruses using a commercially available multi-
plexed polymerase chain reaction (PCR) (AusDiagnostics, 
Sydney, Australia). During the study period there were 
approximately four to five PCR runs per day, depending upon 
the number of samples received. Diagnostic test results were 
automatically uploaded to hospital electronic microbiology 
records which were immediately accessible to clinical teams. 
In addition, positive influenza A/B results were telephoned 
through to clinical teams by microbiology staff, usually 
within 2 h of result availability. During intervention periods, 
samples were tested using a point- of- care (POC) strategy; an 
eight- cartridge GeneXpert Xpress Flu A and B/RSV analyser 
(Cepheid, Sunnyvale, CA, USA) was located on the RAU and 
samples were processed by trained ward staff according to 
manufacturer instructions. GeneXpert was available to use 
24 h a day. The POC service was managed by the Pathology 
POC team and included initial verification of samples tested 
against the laboratory, ongoing weekly quality assurance 
testing, training of all Ward Authorised Trainers and other 
staff using a Standard Operating Procedures and Competency 
template, and continuing verification of results logged into 
the hospital and laboratory IT systems. Results were avail-
able within 30 min from introduction of the sample into the 
analyser and printed off as hard copies on RAU and placed 
in the front of medical notes for notification to the medical 
team (Fig. 2). For negative POC tests, multiplex PCR testing 
Fig. 1. Timeline of the point- of- care and laboratory multiplex PCR respiratory virus testing periods.
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was only done when requested by a clinician and was not 
performed as a default. There was no test selection based upon 
the severity of symptoms or other patient factors during either 
the control or intervention periods.
For all patients, routinely recorded data were collected from 
hospital information systems regarding time from admis-
sion to result, length of stay and time to patient isolation in 
accordance with local infection control policies. This study 
was part of clinical evaluation of the implementation of a new 
diagnostic process within the hospital. Therefore, individual 
patient consent was not obtained; all data were anonymised 
prior to analysis.
From historical laboratory data collected during the previous 
two influenza seasons, it was predicted that 720 patients on 
the study ward would be tested by either POC test or in the 
laboratory during the study period. Based on an estimated 
mean length of stay of 123 h for laboratory- tested patients 
with a group standard deviation of 162 h and assuming a 
POCT to laboratory- testing ratio of 2.75 : 1, this sample size 
was estimated to have 80 % power to detect a 31 % decrease 
in mean length of stay in people tested by POCT with a 
significance level (alpha) of 0.05. However as this was not a 
clinical trial, we did not plan to recruit to a set sample size and 
all eligible patients who were tested during the study period 
were included in the analyses.
Length of stay was calculated in hours as the difference between 
the recorded time of admission and the time of discharge. 
For POCT, turnaround time was defined as the number of 
hours between admission to the ward and notification of the 
test result, and for laboratory- testing as the number of hours 
between admission to the ward and electronic transcription 
of the results. For patients who tested positive for a respiratory 
virus, the time to appropriate institution of infection control 
measures was calculated as the time from admission to the 
first recorded time of patient isolation either in a side- room, 
or in an ‘infection cohort bay’. Patients who were not isolated 
are henceforth described as being managed on an ‘open bay’.
Statistical analysis
The frequency of test results were summarised for POC and 
laboratory- tested patients. Baseline Charlson co- morbidity 
index scores were compared between the groups using the 
Fig. 2. Flow chart of influenza testing during intervention and control periods RAU, Respiratory Assessment Unit; ARTI, Acute Respiratory 
Tract Infection; POCT, Point- of- care test; PCR, Polymerase Chain Reaction; TAT, Turnaround time.
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two sample Wilcoxson rank- sum test. Continuous outcomes 
were analysed after transformation of the data to correct for 
right- skewed distribution. Length of stay and turnaround 
time data were log- transformed and time to instigation of 
control measures were cube- root transformed, with the 
decision on transformation type being made on the distri-
bution of the data and numbers. The variance between the 
groups was compared using Levene’s test and the means of 
the laboratory- tested and POC- tested groups compared in 
an independent t- test with Satterthwaite’s correction for 
unequal variance if appropriate. Geometric means were 
obtained through back- transformation of data. For the 
length of stay analyses we used a linear regression model 
to adjust for Charlson co- morbidity index score. Subgroup 
analyses by test result were conducted.
For patients who were isolated immediately upon admission 
but who subsequently tested negative for a respiratory virus, 
the time to ‘de- isolation’ (move from isolation to an open 
bay) was estimated for the group as a whole. This calculation 
was based on the assumption that the proportions of positive 
and negative patients who were isolated immediately upon 
admission were similar and that patients were removed from 
isolation immediately upon receipt of a negative result.
All analyses were conducted in Stata 15.1.
RESuLTS
In total, 1161 patients were admitted to RAU during the study 
period and tested for respiratory viruses. Excluding patients 
in whom test results were invalid (n=16), 1145 patients 
remained in the analyses; POC tested (n=755), laboratory 
tested (n=390). The median Charlson co- morbidity index 
scores were 4 (IQR 0–9) for POC tested patients and 4 (IQR 
0–7) for those tested by the laboratory (P=0.15).
A respiratory virus was identified in 164 (21.7 %) of POC- 
tested patients and 138 (35.4 %) of laboratory- tested patients. 
Influenza virus was the predominant pathogen identified in 
both groups. The mean time from admission to availability of 
the result to the clinical team (turnaround time) was signifi-
cantly shorter in the POC group compared to the control 
group (2.9 h (95 % CI 2.9 to 3.1) versus 31.2 h (95 % CI 29.6 
to 32.9), P<0.001).
Time to patient isolation
Overall, the mean time spent on the open bay prior to isola-
tion was significantly shorter for patients who tested positive 
for influenza or RSV in the POC group compared to the 
laboratory- tested group (mean difference (MD) 16.9 hours 
P<0.001). On subgroup analysis according to pathogen, a 
significantly shorter mean time to isolation was noted for 
patients positive for influenza in the POC group compared 
to laboratory- tested group (MD 10.8 h, P<0.001). For RSV 
positive patients, there was no significant difference in time 
spent on the open ward between POC versus laboratory- 
tested groups (Table 1). Ta
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In total, 35 of 252 (13.9 %) patients who eventually tested 
positive for a respiratory virus by either POC or in the lab, 
were isolated immediately upon admission. The proportion of 
influenza or RSV positive patients who were on the open ward 
24 h or more after admission was significantly greater in the 
POC group (44.4 vs 8.6 %, odds ratio 8.4, 95 % CI 4.2 to 16.8, 
P<0.0001) (Table 2). Data on time to isolation for patients 
who eventually tested negative were not captured.
In a sensitivity analysis, assuming that the time to patient 
isolation is similar in those who eventually test negative as 
test positive, and that patients are ‘de- isolated‘ immediately 
upon receipt of a negative test result, POC testing potentially 
saved 2802 isolation hours (or 116.75 isolation bed- days) over 
the 18 week period, based on 140 laboratory- tested patients 
and 540 POC tested patients who were isolated within 24 h of 
admission but were eventually test negative. If patients were 
isolated immediately upon admission, there was a potential 
saving of 3198 isolation hours (or 133 isolation bed- days) 
over the 18 week period based on 117 patients who were 
isolated immediately upon admission but were eventually 
test negative.
Length of stay
The mean length of stay for all patients admitted and tested for 
respiratory viruses during the study period was 129.1 h (SD 
167.6), median 77 h (IQR 32–157). Patients who had a respira-
tory virus detected by either test had an average LOS that was 
significantly shorter than those in whom no respiratory virus 
was found (adjusted means for negative and positive patients 
74.7 h (95 % CI 69.1 to 80.9) versus 56.7 (95 % CI 49.7 to 64.7), 
P<0.01, respectively), Table 3.
Patients who tested positive in the POC group had a shorter 
LOS compared to those in the laboratory- tested group 
(adjusted mean length of stay 48.8 h (95 % CI 52.6 to 64.3) v 
64.3 h (95 % CI 40.6 to 58.5), P=0.05).
Within the POC group, those who tested positive for either 
influenza or RSV were discharged on average 25 h earlier than 
those who tested negative (adjusted means 50.3 (95 % CI 41.8 
to 60.5) versus 75.2 (95 % CI 68.3 to 82.9), P<0.01, respec-
tively). Patients positive for influenza were discharged on 
average almost 27 h earlier than influenza- negative patients 
(adjusted mean 48.5 (95 % CI 40.1 to 26.7) versus 75.2 (95 % 
CI 68.3 to 82.9), P<0.01, respectively).
Within the laboratory- tested group, there was no significant 
difference in LOS between patients who tested positive for 
respiratory viruses and those who tested negative.
Based on the observation that patients with a positive result 
in the POC group were discharged approximately 15.5 h 
earlier than corresponding patients in the laboratory- tested 
group (P=0.05), an estimated 106 bed- days were saved in total 
during the POC ‘on- period’ of 18 weeks (equivalent to 9.6 
bed- days per week). A comparable difference in mean LOS 
was also seen in a sensitivity analysis in which only patients 
who were admitted during the peak influenza season (weeks 
51 to 13) were included (n=261, adjusted mean difference 
18.6 h, P=0.03).
dISCuSSIon
The main finding from our study is that implementation of 
POC testing delivered benefits to patient care admitted to 
hospital with respiratory illness in terms of more rapid confir-
mation of infection with influenza and RSV, a shorter length 
of stay and more rapid isolation of patients testing positive 
for influenza or RSV.
Time to isolation
The reduction in time to isolation, either in a single use side 
room or a cohort bay for influenza positive patients, during 
periods when POC was operational, demonstrates the benefit 
of rapid diagnostics for infection prevention and control of 
respiratory viruses. The time to isolation of POC influenza 
positive patients was close to that of the turnaround time to 
results (~3 h). The mean time to isolation of laboratory tested 
influenza positive patients was 13 h whereas the mean turna-
round time of result was 31 h. Thus, many patients are isolated 
empirically whilst awaiting results. POC allowed earlier 
release of isolation beds for negative patients allowing more 
efficient use of limited isolation resources. Our study indicates 
that the introduction of POC testing could potentially save 
between 6.5 to 7.5 isolation bed- days per week during the 
winter. The mean time to isolation for of RSV positive patients 
was not statistically different and was 35 h in the POC group. 
This likely reflected a prioritisation of isolation facilities for 
influenza positive patients within the setting on an adult 
respiratory ward, given the relative severity of its impact on 
morbidity and clinical sequelae.
Isolation facilities such as side rooms are at a premium in 
winter months when a large number of patients with respira-
tory symptoms are admitted to hospital. Frequently there 
are insufficient side rooms available to isolate all patients 
suspected to have a respiratory virus infection and there 
are also requirements to isolate those with other infec-
tions such as carbapenem- resistant Enterobacteriaceae, 
Table 2. Time to isolation for patients testing positive for influenza or 
RSV per test type
Time to isolation 
(hours)
POC tested: 
number isolated 
by the specified 
time point (%) 
N=162
Laboratory 
tested: number 
isolated by the 
specified time 
point (%)
N=90
P- value (Chi- 
squared test)
0 30 (18.5) 5 (5.6) 0.004
≤1 h 44 (27.2) 16 (17.8) 0.09
≤6 h 102 (63.0) 24 (26.7) <0.001
≤12 h 130 (80.2) 30 (33.3) <0.001
≤24 h 148 (91.4) 50 (55.5) <0.001
More than 24 h 14 (8.6) 40 (44.4) <0.001
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methicillin- resistant Staphylococcus aureus and Clostridium 
difficile infection.
Rapid point of care testing allows the rapid identification of 
those with confirmed infection and for the more judicious use 
of side rooms, personal protective equipment and anti- virals. 
Previous studies [15, 17, 18] have demonstrated the utility 
of POCT to de- isolate patients more promptly when not 
required. Rapid isolation is important for effective infection 
control within the hospital. In previous years we have seen the 
consequences of poor isolation practice with increased use of 
oseltamivir for post- exposure prophylaxis and nosocomial 
transmissions within the trust. In 2017/8 this was estimated 
to be 15 % of influenza cases diagnosed during the influenza 
season. A recent study using phylogenetic analysis of influ-
enza isolates demonstrated genetic clustering in 15.8 % of 
hospital influenza cases indicating nosocomial acquisition 
[19]. Nosocomial acquisition of influenza has knock- on 
effects in terms of morbidity and delays to discharge, the 
financial impact of which has not been clarified and further 
studies are needed to understand the economic effects of these 
aspects in more detail. A previous study of the introduction 
of POC testing in the emergency department together with a 
dedicated influenza ward demonstrated benefits in terms of 
reduction of hospital acquired influenza [10].
Implementation of the rapid POC test was well received 
by staff and patients alike who, when surveyed all reported 
wanting the service to be available in future years. Patient 
feedback received was universally positive, with many citing a 
reduction in anxiety due to the uncertainty of their diagnosis 
and improved confidence in the care they receive. Clinicians 
noted the benefits of POC testing in terms of aiding clinical 
decision making around anti- viral and antimicrobial use, 
although this was not formally assessed in our study. Other 
studies have formally assessed the benefits of POC testing in 
terms of more timely and judicious use of anti- viral prescrip-
tions [20] antibiotic usage [15, 21, 22] and other microbio-
logical investigations [23].
Length of stay
Several studies have shown that POCT for viral respiratory 
infections is associated with multiple benefits, including a 
shorter length of stay for those testing positive [15, 21, 23, 24]. 
Possible explanations include improved clinician confidence 
Table 3. Length of stay in POC and laboratory- tested groups according to test results
Comparison Number included in 
analysis
Unadjusted MD LOS 
(hours)
P value Adjusted MD LOS* P value
Positive vs negative result
Any test (Laboratory/POCT) 1144 −20.1 <0.01 −18.1 <0.01
POCT only 755 −26.5 <0.01 −24.9 <0.01
Laboratory only 389 −11.2 0.17 −8.7 0.28
Influenza positive vs negative
Any test (Laboratory/POCT) 1055 −22.36 <0.01
POCT only 743 −26.68 <0.01
Laboratory tested only 312 −9.7 0.37
RSV positive vs negative
Any test (Laboratory/POCT) 883 −.4.6 0.73
POCT only 603 4.7 0.86
Laboratory tested only 280 −8.6 0.73
POCT vs laboratory
Any result (positive or negative) 1144 −1.622 0.75 −3.38 0.51
Any positive 302 −14.4 0.0639 −15.5 0.05
Influenza positive only 213 −16.3 0.11
RSV positive only 12.7 0.68
Negative 842 −1.0 0.88 0.97 0.94
*Adjusted for Charlson morbidity index
MD, mean difference; LOS, length of stay.
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in discharging patients with a confirmed respiratory virus 
infection and the association between earlier anti- viral initia-
tion and shortened hospitalisation [25].
The reduction in LOS has important economic benefits. In 
terms of bed- day savings this equated to ~nine bed- days 
per week which over an 18 week flu season could translate 
to approximately £48 600 (based on an estimate of £300 per 
bed- day). In addition patient flow is optimised as bed- days 
saved can help with pressure in the emergency department 
(ED) which faces time constraints to transfer patients onto 
admitting wards, in order to free up bed capacity. A previous 
study utilizing the GeneXpert platform for influenza esti-
mated reductions in costs of testing and treating patients by 
103€ per ED patient and 64€ per hospitalized patient [26].
Turnaround time
The reduction in turnaround time with POC testing has 
been well documented in previous studies [15, 23, 24] and in 
our study this difference likely reflects the time spent for the 
specimen to reach the centralised laboratory on a different 
hospital site and the fact that samples are batch tested in the 
laboratory at regular intervals within laboratory working 
hours. We took the turnaround time to be the time between 
sampling and availability of the result to the clinical team, not 
the time at which results were phoned through to the ward, so 
it is unlikely that the speed of this process could be increased.
Strengths and limitations of study
The strengths of this study include its utilization of real- world 
routinely collected clinical data which enhances the general-
isability and reproducibility of our findings. We specifically 
restricted our analyses to one patient group – those admitted 
with primary respiratory complaints rather than include those 
from other patient groups such as haematology and oncology 
patients whose teams were also able to access the point of 
care testing service. In addition, we conducted the study over 
one influenza season to reduce the effect of cofounding vari-
ables such as type of circulating influenza and prevalence of 
influenza between subsequent years.
Due to lack of randomisation there is potential for bias in 
terms of the time in which POC was utilised in the course of 
the winter season. The control period was mainly when RSV 
was the predominant virus and intervention period mainly 
when influenza was circulating, which may have introduced 
bias in terms of outcomes. Sensitivity analysis restricted to 
admissions during the weeks when influenza hospitalisations 
were above baseline threshold levels confirmed the signifi-
cantly decreased mean LOS in POC tested patients. Although 
results of outcomes studied are similar when adjusted for type 
of pathogen, isolation facilities may have been under different 
levels of constraint at different time points in the flu season. 
It is notable that a larger percentage of patients in the POC 
group were isolated immediately upon admission and there 
may have been a bias to those who were quickly suspected to 
have and tested for influenza.
We utilised an interrupted series design that was powered 
for differences in length of stay primarily. This meant that 
the control vs intervention periods were of unequal lengths 
and at differing time points in the influenza season. In addi-
tion, we did not assess the impact that POC testing had on 
time to initiation of anti- virals or reduction in antibiotic use, 
as these outcomes have been reported previously by other 
investigators.
Although our study suggests a benefit in terms of more rapid 
isolation of patients with influenza, a further study would 
be required to assess the impact in terms of a reduction of 
onward transmission in this particular setting.
ConCLuSIon
Introduction of a POC testing strategy for influenza and RSV 
infection in adults admitted with acute respiratory illness was 
associated with more rapid reporting of results, more appro-
priate isolation practices and reductions in LOS compared to 
laboratory testing.
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